title: Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.
abstract: OBJECTIVE
  A prospective study to evaluate the role of fludarabine alone or in combination with idarubicin in untreated patients with mantle cell lymphoma (MCL).
  
  
  METHODS
  Twenty-nine untreated patients with mantle cell lymphoma were stochastically treated with intravenous fludarabine at a dose of 25 mg/m(2)/day for 5 days (11 patients) or with a combination of fludarabine and idarubicin (FLU-ID) (fludarabine 25 mg/m(2) i.v. on days 1 to 3 and idarubicin 12 mg/m(2) i.v. on day 1 (18 patients). For both regimens, cycles were given at three-week intervals for a total of six courses. According to the International Prognostic Index, the most part of high-intermediate and high risk factor patients were in the FLU-ID subset: 7 (39%) patients vs. 2 (18%) in the fludarabine alone subset.
  
  
  RESULTS
  Of the 29 patients, 8 (28%) obtained a complete response and 10 (35%) a partial response, with an overall response rate of 63%. The remaining 11 (37%) patients did not respond to the therapy. The overall response rates were 64% (7 patients) in the fludarabine group and 61% (11 patients) in the FLU-ID group. The complete response rate was 27% (3 patients) for fludarabine and 28% (5 patients) for FLU-ID. The toxicity was mild in terms of neutropenia and infections, and no fatalities occurred due to drug-induced side effects.
  
  
  CONCLUSIONS
  These results suggest the efficacy of fludarabine alone or in combination with idarubicin in MCL patients. It will be important to increase this experience and to assess other fludarabine-containing regimens, in particular with cyclophosphamide plus idarubicin and with mitoxantrone and or cyclophosphamide, to test the true role of this approach in MCL.
authors.affiliation: Istituto di Ematologia e Oncologia Medica "Seràgnoli", Policlinico S.Orsola, via Massarenti 9, 40138 Bologna, Italy.
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: M
authors.initials: M
authors.lastname: Magagnoli
authors.forename: L
authors.initials: L
authors.lastname: Moretti
authors.forename: R
authors.initials: R
authors.lastname: Battista
authors.forename: F
authors.initials: F
authors.lastname: Ronconi
authors.forename: A
authors.initials: A
authors.lastname: De Renzo
authors.forename: A
authors.initials: A
authors.lastname: Zaccaria
authors.forename: P
authors.initials: P
authors.lastname: Gentilini
authors.forename: L
authors.initials: L
authors.lastname: Guardigni
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: C
authors.initials: C
authors.lastname: Cellini
authors.forename: P P
authors.initials: PP
authors.lastname: Fattori
authors.forename: M
authors.initials: M
authors.lastname: Bendandi
authors.forename: M
authors.initials: M
authors.lastname: Bocchia
authors.forename: E
authors.initials: E
authors.lastname: Aitini
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000633:toxicity; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine; D015255:Idarubicin